Alder-话题@MedSci

#Alder#

6篇内容 | 708人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, objectType=article, longId=193590, objectId=16b6193590e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16b6193590e7, replyNumber=0, likeNumber=49, createdTime=2020-05-08, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16b6193590e7, moduleTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16b6193590e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗, objectType=article, longId=180539, objectId=0783180539fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0783180539fc, replyNumber=0, likeNumber=45, createdTime=2019-10-07, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0783180539fc, moduleTitle=Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0783180539fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587547, encodeId=197c158e547c2, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利, objectType=article, longId=179627, objectId=a28c1e962734, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a28c1e962734, replyNumber=0, likeNumber=18, createdTime=2019-09-19, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a28c1e962734, moduleTitle=Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a28c1e962734)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587546, encodeId=1049158e54628, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处, objectType=article, longId=161547, objectId=a8ea16154e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8ea16154e26, replyNumber=0, likeNumber=51, createdTime=2019-03-04, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8ea16154e26, moduleTitle=Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8ea16154e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Alder Bio制药报告了Eptinezumab慢性偏头痛的的新近进展, objectType=article, longId=142039, objectId=7e6214203922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e6214203922, replyNumber=0, likeNumber=38, createdTime=2018-07-02, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e6214203922, moduleTitle=Alder Bio制药报告了Eptinezumab慢性偏头痛的的新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e6214203922)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587544, encodeId=5f2c158e544c3, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, objectTitle=Alder公司授权Vitaeris开发IL-6新药, objectType=article, longId=68076, objectId=fdfc680e617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc680e617, replyNumber=0, likeNumber=38, createdTime=2016-05-14, rootId=0, userName=xuqianhua, userId=e79417492785, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc680e617, moduleTitle=Alder公司授权Vitaeris开发IL-6新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc680e617)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alder

2020-05-29

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇

2020-05-08

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗

2019-10-07

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利

2019-09-19

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处

2019-03-04

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Alder Bio制药报告了Eptinezumab慢性偏头痛的的新近进展

2018-07-02

xuqianhua (审核中...)

前往app查看评论内容

#Alder#

Alder公司授权Vitaeris开发IL-6新药

2016-05-14

科室
- - 订阅+
  - 更多科室
工具
服务